Position in ARQT
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$7,448,184
-$826,488 QoQ
Shares Held
284,065
-19.1% QoQ
Ownership
0.226%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#60
of 271 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ARQT Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026FIRST TRUST ADVISORS LP holds $2,844,450,753 across 98 Biotechnology names. ARQT ranks #49 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
547,132 | $341,158,687 | |
| 2 | INCY |
Incyte Corp
|
1,587,996 | $180,015,226 | |
| 3 | CORT |
Corcept Therapeutics Inc
|
1,829,545 | $159,078,937 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
289,179 | $143,643,884 | |
| 5 | EXEL |
Exelixis, Inc.
|
2,543,353 | $138,383,836 | |
| 6 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
421,534 | $126,894,380 | |
| 7 | KRYS |
Krystal Biotech, Inc.
|
324,900 | $120,755,583 | |
| 8 | AXSM |
Axsome Therapeutics, Inc.
|
482,061 | $117,994,070 |
All Filings in ARQT
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $7,448,184 | 284,065 | Shares | Sole | 2026-08-11 | |
| 2026-03-31 | $8,274,672 | 351,217 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $11,751,152 | 404,654 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $4,240,590 | 224,965 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $4,788,124 | 341,521 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $6,884,493 | 440,185 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $3,665,498 | 263,137 | Shares | Sole | 2025-02-13 | |
| No filing history on record for this holder in this stock. | ||||||